Can AI reduce false positives and biopsies in breast ultrasound exams?

An AI system trained on breast ultrasound studies showed promise in reducing false positives and biopsies by over 37% and 28%, respectively, while maintaining sensitivity, potentially aiding clinical decision-making. Second, nirsevimab demonstrated effectiveness in preventing RSV infections and hospitalizations among infants, with protection waning over time but remaining significant. Lastly, breast and colon cancer screening rates in the U.S. have surpassed pre-pandemic levels, but cervical cancer screening rates remain concerningly low, highlighting disparities in access to preventive care.